{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T09:40:14.980827+00:00","company":{"ticker":"BCAX","cik":2023658,"company_name":"Bicara Therapeutics Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"60ab645046b356e1935e5f244f16344ec79f922c","cik":2023658,"ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-05-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss totaled $56.2 million for the first quarter of 2026","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-11","result_type":"reported_results","revenue_text":null},"claim":"Bicara Therapeutics Inc. reported the first quarter ended March 31, 2026 results: net income Net loss totaled $56.2 million for the first quarter of 2026.","evidence_excerpt":"Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-033135","anchor_url":"https://secwatch.observer/filing/0001628280-26-033135#claim-60ab645046b356e1935e5f244f16344ec79f922c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/0001628280-26-033135-index.htm"},{"fact_type":"earnings_release","fact_key":"90a0683d59be16d2c984f8028bcba4975ab1ee27","cik":2023658,"ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti","period_text":"the fourth quarter and full year ended December 31, 2025","report_date":"2026-03-30","result_type":"reported_results","revenue_text":null},"claim":"Bicara Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti.","evidence_excerpt":"On March 30, 2026, Bicara Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-021868","anchor_url":"https://secwatch.observer/filing/0001628280-26-021868#claim-90a0683d59be16d2c984f8028bcba4975ab1ee27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026021868/0001628280-26-021868-index.htm"},{"fact_type":"material_agreement","fact_key":"5967876b1f00ae1cadd96488c82741c951686e47","cik":2023658,"ticker":"BCAX","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives","effective_date":"2026-02-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).","evidence_excerpt":"On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-076560","anchor_url":"https://secwatch.observer/filing/0001193125-26-076560#claim-5967876b1f00ae1cadd96488c82741c951686e47","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/0001193125-26-076560-index.htm"}]}